Medical Degree: Virginia Commonwealth University/Medical College of Virginia
Internship & Fellowship: Walter Reed Army Medical Center
Undergraduate Degree: Princeton University
Glenn W. Wortmann, MD, FIDSA, FACP is the Section Director of Infectious Diseases at MedStar Washington Hospital Center, Washington, DC and the Medical Director of Infection Prevention at the MedStar Institute of Quality and Safety. He maintains academic appointments at Georgetown University Medical Center as a Professor of Clinical Medicine and at the Uniformed Services University of the Health Sciences as Professor of Medicine.
During his time in the U.S. Army, he served as a general medical officer in Germany, as an internist at Ft. Eustis, as the ID Fellowship Program Director and Chief of Infectious Diseases at Walter Reed and deployed to combat support hospitals in Afghanistan and Iraq. His research centered on leishmaniasis, and he was the co-inventor of the Leishmania PCR assay which was cleared for human testing and published papers related to diagnostics and therapeutics. He also conducted research related to war-trauma and reported the impact of Acinetobacter bacteremia, the colonization of war-trauma patients with multi-drug-resistant bacteria and the nephrotoxicity of colistin.
He retired from the military in 2012 at the rank of Colonel and transitioned to the MedStar Washington Hospital Center where he serves as the Section Director of Infectious Diseases and the Chair of the Infection Prevention committee. He served as the Program Director of the MedStar Washington Hospital Center ID Fellowship from 2012-2017.
Recent Publications:
1. Jakharia K, Ilaiwy G, Moose S, Appalla L, Waga M, McAlduff J, Karanfil L, McGann P, Wortmann G. Use of whole genome sequencing to guide a Clostridiodes difficile diagnostic stewardship program. Infect Control Hosp Epidemiol 2019;40:804-806.
2. Iqbal S, Overcash R, Mokhtari N, Saeed H, Gold S, Auguste T, Imrza M, Ruiz M, Chahine J, Waga M, Wortmann G. An uncomplicated delivery in a patient with COVID-19 in the United States. N Engl J Med 2020;e34. Doi: 10.1056/NEJMc2007605. Epub 2020 Apr 1.
3. Barat B, Das S, De Giorgi V, Henterson DK, Kopka S, Lau A, Miller T, Moriarty T, Palmore T, Sawney S, Spalding C, Tanjutco P, Wortmann G, Zelazny A, Frank KM. Pooled saliva specimens for SARS-CoV-2 testing. J Clin Microbiol 2021; 59(3);e02486-20.
4. Costello V, Sowash M, Gaur A, Cardis M, Pasieka H, Wortmann G, Ramdeen S. Imported monkeypox from international traveler, Maryland, USA 2021. Emerg Infect Dis 2022;28(5)
5. Luterbach CL, Chen L, Komarow L, Ostrowsky B, et al, Wortmann G, et al. Transmission of carbapenem-resistant Klebsiella pneumoniae in US hospitals. Clin Infect Dis 2023 76:229-237.
6. ACTIV-3/TICO Study Group, Barkauskas C, Mylonakis E, et al. Efficacy and safety of ensovibep for adults hospitalized with COVID-19: a randomized controlled trial. Ann Intern Med 2022;175:1266-1274.
7. Cummings, JF, Polhemus ME, Kester KE, et al. A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated ASO2 adjuvant in healthy, malaria-naïve adults. Vaccine 2024;42:3066-3074.
8. Wiesner L, Flinn J, Brewer B, et al. Building clinical care capacity for patients with special pathogens in advance of the next outbreak. Health Secur 2024;22(S1): S66-S75.
9. McCarthy J, Wortmann G, Kirchhoff L. Drugs for protozoal infections other than malaria. In: M Blaser, et al (Eds), Principles and Practice of Infectious Diseases. Elsevier Saunders, Philadelphia, PA. 2025:566-574